Suzhou ColorTech Bio Secures Tens of Millions of RMB in Series A Funding to Advance Multiplexed Single-Molecule Detection Platforms

VCBeat has learned at the earliest opportunity,Suzhou Lychix Biotechnology Co., Ltd. (hereinafter referred to as “Suzhou Lychix”) has recently completed a Series A financing round worth tens of millions of yuan,This round of financing was led by IDG Capital, with follow-on investment from Borui Medicine. The funds raised will be primarily used to further invest in the company’s R&D, build its talent team, and file for medical device registration certificates.

Suzhou Lychix, established in 2018, is a company providing research tools for the life sciences. It has been dedicated to developing high-efficiency technology platforms to mine massive, high-resolution life science data, particularly in the field of multiplex protein detection. Currently, the company possesses its core technology platform—Ultra-high-sensitivity biomolecular detection platform and multiplex magnetic-fluorescent encoded microsphere platform, along with Medivh series reagents and equipment products.

In recent years, significant breakthroughs have been made in protein detection methods, with ultramicro reaction systems substantially enhancing detection sensitivity. As biological macromolecules that play critical roles in nearly all biological processes, proteins can be analyzed at high resolution to effectively improve the assessment of an organism’s health status through comprehensive proteomic profiling.

In human blood, there are approximately 10,500 known secreted proteins, but conventional immunoassays can detect fewer than 1,300 of them. Single-molecule detection technology can increase this number to approximately 9,200.

Compared with traditional detection technologies,Single-molecule detection technology offers advantages such as high resolution, high sensitivity, low background signal, low sample volume requirements, and short analysis time.Capable of detecting low-abundance proteins in complex samples, enabling differentiation between health and disease states as well as monitoring of disease onset and progression.

The multiplex single-molecule detection technology provided by Suzhou Lychix can be widely applied in the departments of neurology, cardiology, and clinical pharmacology at hospitals.It plays a crucial role in assessing the early likelihood of disease onset and detecting biomarkers at extremely low levels.

Dr. Cheng Peng, Founder and CEO of LychixLychix told VCBeat, “The Lychix team began exploring high-throughput single-molecule research solutions during the ‘$1,000 genome’ era and has witnessed the rapid advancement of next-generation sequencing technologies at a pace surpassing Moore’s Law. Now, we aim to replicate this success in the field of protein research.”

The Lychix team believes that researchers can obtain large volumes of data more efficiently through a multiplex protein detection technology platform with higher sensitivity. Currently, Lychix is collaborating with multiple domestic and international research institutes, hospitals, and pharmaceutical companies, while advancing both basic and clinical research. This round of financing will help the company actively expand into different application areas, accelerate product promotion, and continue to develop technology platforms that enhance the resolution and data output of life sciences research, thereby making greater contributions to the field.